Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
- Details
- Category: Pfizer

Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
- Details
- Category: Roche

Bayer Consumer Health leaders propose new principles for science-led self-care
- Details
- Category: Bayer

GSK signs agreement to support pandemic preparedness in Europe
- Details
- Category: GlaxoSmithKline

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design
- Details
- Category: Pfizer

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager
- Details
- Category: AstraZeneca

The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.
Pfizer and BioNTech complete submission to European Medicines Agency for Omicron BA.1 adapted bivalent vaccine candidate
- Details
- Category: Pfizer

More Pharma News ...
- Bayer to sell men's health product Nebido™ to Grünenthal
- Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government
- Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
- Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
- FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
- GSK completes acquisition of Sierra Oncology
- Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine